Investment analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
PULM stock opened at $2.06 on Friday. The company has a 50 day simple moving average of $2.09 and a 200 day simple moving average of $1.97. The stock has a market cap of $7.52 million, a price-to-earnings ratio of -0.85 and a beta of 0.99. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The firm had revenue of $1.55 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- Market Cap Calculator: How to Calculate Market Cap
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- When to Sell a Stock for Profit or Loss
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What Are Trending Stocks? Trending Stocks Explained
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
